NCT03048474View on ClinicalTrials.gov

Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma

PHASE2CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2019

Conditions

Malignant Pleural Mesothelioma

Interventions

DRUG

nivolumab and ipilimumab

Trial Locations (1)

1066CX

Netherlands Cancer Institute-Antoni van Leeuwenhoek Ziekenhuis, Amsterdam

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER

NCT03048474 - Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma | Biotech Hunter | Biotech Hunter